<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03252834</url>
  </required_header>
  <id_info>
    <org_study_id>B-ER-106-120</org_study_id>
    <nct_id>NCT03252834</nct_id>
  </id_info>
  <brief_title>Genetic Variants and Chemotherapy-induced Abnormal Thermal Sensation</brief_title>
  <official_title>To Study the Individual Variants of Chemotherapy-induced Abnormal Thermal Sensation in Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cheng-Kung University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single arm, single center study evaluating the use of a 4-gene panel
      to predict the occurrence of chemotherapy-induced abnormal thermal threshold in endometrial
      and ovarian cancer patients receiving post-operative chemotherapy with
      Carboplatin/Paclitaxel, and stage III colorectal cancer patients receiving adjuvant
      chemotherapy with mFOLFOX6. A total of 100 patients will be enrolled during 2017 July~ 2019
      June. Blood sample will be collected before chemotherapy to analyze the genetic variants of
      TRPV1, TRPM2, TRPA1 and ORAI1. All patients will receive neurologic examination (Quantitative
      Sensory Test, QST) and complete the questionnaires for quality of life (EQ5D &amp; CIPN20). The
      primary endpoint of this study is to test if the genetic variant of TRPV1, TRPM2, TRPA1, and
      ORAI1 is a predictive biomarker for the chemotherapy-induced abnormal thermal sensation in
      cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The change of thermal pain threshold</measure>
    <time_frame>before chemotherapy &amp; 3, 6, and 9 months after chemotherapy</time_frame>
    <description>The threshold of detecting heat-induced pain</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chemotherapy-induced Abnormal Thermal Sensation</condition>
  <arm_group>
    <arm_group_label>Patients with endometrial or ovarian cancer</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with colorectal cancer</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Genetic variants of TRPV1, TRPM2, TRPA1 and ORAI</intervention_name>
    <description>Genetic variants of TRPV1, TRPM2, TRPA1 and ORAI1 will be analyzed. Quantitative Sensory Test, QST, will be used to determined if there is abnormal thermal sensation.</description>
    <arm_group_label>Patients with endometrial or ovarian cancer</arm_group_label>
    <arm_group_label>Patients with colorectal cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Colorectal, endometrial, or ovarian cancer patients who are scheduled to receive
        post-operative adjuvant chemotherapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 20 years old

          -  Pathological stage I~IV for ovarian cancer, stage II~IV for endometrial cancer, or
             stage III for colorectal cancer.

          -  Scheduled to receive adjuvant Paclitaxel/Carboplatin for ovarian or endometrial
             cancer, or mFOLFOX6 for colorectal cancer.

          -  Patient willing to provide blood sample for research purposes.

          -  Ability of the patient to provide informed consent.

        Exclusion Criteria:

          -  Prior treatment with neurotoxic chemotherapy, such as oxaliplatin, cisplatin,
             carboplatin, taxanes or vinca alkaloids.

          -  Receiving chemotherapy within 6 months.

          -  A family history of a genetic or familial neuropathy

          -  Poor compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meng-Ru Shen, PHD</last_name>
      <phone>+886-6-2353535</phone>
      <phone_ext>5505</phone_ext>
      <email>mrshen@mail.ncku.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2017</study_first_submitted>
  <study_first_submitted_qc>August 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2017</study_first_posted>
  <last_update_submitted>August 16, 2017</last_update_submitted>
  <last_update_submitted_qc>August 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cheng-Kung University Hospital</investigator_affiliation>
    <investigator_full_name>Meng-Ru Shen</investigator_full_name>
    <investigator_title>Associate Dean for Research</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

